News about "inflammatory diseases"

Johns Hopkins Researchers Identify Human Resistin as Key Driver of Inflammatory Pathway

Researchers found that blocking human resistin with a targeted antibody reduced activation of the NLRP3 inflammatory pathway, pointing to a potential target for future therapies.

Inflammatory Diseases | 07/09/2026 | By News Bureau |  109

Can-Fite BioPharma Secures Australian Patent for Namodenoson in Advanced Metastatic Cancer

Can-Fite BioPharma has secured an Australian patent covering the use of Namodenoson for advanced metastatic cancer, strengthening intellectual property protection as the drug advances through late-stage clinical development for liver and pancreatic cancers.

Inflammatory Diseases | 15/07/2026 | By News Bureau |  137

AbbVie to Acquire Apogee Therapeutics

AbbVie plans to acquire Apogee Therapeutics, expanding its immunology portfolio with a diverse pipeline of innovative therapies for dermatologic, respiratory, inflammatory, and immune-mediated diseases.

Inflammatory Diseases | 23/06/2026 | By News Bureau |  155

QureBio Reports Promising Phase Ib/II Data for Q-1802 in Advanced Gastric and GEJ Cancer

ASCO 2026 data show strong response rates and manageable safety for the bispecific antibody Q-1802 plus XELOX, supporting progression to a Phase III trial.

Inflammatory Diseases | 29/01/2026 | By News Bureau |  589

Sanofi Names Montpellier Global Hub for Autoimmune Disease Research

Sanofi, in partnership with the Immun4Cure University Hospital Institute in Montpellier, has launched a Translational Centre of Excellence focused on developing treatments for autoimmune and inflammatory diseases. The centre aims to place patients at the core of R&D, spanning early research through advanced clinical trials.

Inflammatory Diseases | 16/10/2025 | By Dineshwori |  426

Merck Expands Tulisokibart Phase-2(b) Trials Across Three Inflammatory Diseases

Tulisokibart is an investigational anti-TL1A monoclonal antibody currently in Phase-3 trials for Ulcerative Colitis and Crohn’s disease, to be studied in hidradenitis suppurativa, radiographic axial spondyloarthritis and Rheumatoid Arthritis.

Inflammatory Diseases | 07/10/2025 | By Dineshwori |  662

Accro Bioscience and Fosun Pharma Enter Licensing Deal for AC-201 in Greater China

Accro Bioscience has granted Fosun Pharma exclusive rights to develop, manufacture, and commercialise AC-201 — its independently developed, highly selective TYK2/JAK1 inhibitor — in Greater China (including the Chinese Mainland, Hong Kong SAR, and Macau SAR).

Inflammatory Diseases | 01/09/2025 | By Dineshwori |  394

Matchpoint, Novartis Partner to Develop Oral Inhibitors for Multiple Inflammatory Diseases

Matchpoint Therapeutics has entered into an exclusive option and license agreement with Novartis to develop and commercialise oral covalent inhibitors for multiple inflammatory diseases.

Inflammatory Diseases | 28/07/2025 | By Dineshwori |  255

Evox Therapeutics Appoints Dr. Per Lundin as Chief Executive Officer

Evox Therapeutics Ltd. has announced the appointment of Dr. Per Lundin, Co-Founder and Chief Business Officer as Chief Executive Officer (CEO) and will be appointed to its Board of Directors.

Inflammatory Diseases | 30/04/2024 | By Aishwarya |  1121